Methods and compositions for treating tumors with TTFields and sorafenib
Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.
1. A method of reducing viability of cancer cells, the method comprising:
administering sorafenib to the cancer cells; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz,
wherein the sorafenib is administered to the cancer cells at a therapeutically effective concentration, the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells, and the applying step has a duration of at least 72 hours.
2. The method of claim 1 , wherein the frequency of the alternating electric field is between 120 and 180 kHz.
3. The method of claim 1 , wherein at least a portion of the applying step is performed simultaneously with at least a portion of the administering step.
4. The method of claim 1 , wherein the sorafenib has the general structure:
5. The method of claim 1 , wherein the cancer cells comprise hepatocellular carcinoma cells.
6. The method of claim 1 , wherein the applying step is for an uninterrupted interval of time.
7. The method of claim 1 , wherein the applying step is interrupted by breaks.
8. A method of reducing viability of cancer cells disposed in a body of a living subject, the method comprising:
administering sorafenib to the subject; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz,
wherein the sorafenib is administered to the cancer cells at a therapeutically effective concentration, the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells, and the applying step has a duration of at least 72 hours.
9. The method of claim 8 , wherein the frequency of the alternating electric field is between 120 and 180 kHz.
10. The method of claim 8 , wherein at least a portion of the applying step is performed simultaneously with at least a portion of the administering step.
11. The method of claim 8 , wherein the sorafenib has the general structure:
12. The method claim 8 , wherein the cancer cells comprise hepatocellular carcinoma cells.
13. The method of claim 8 , wherein the sorafenib comprises a pharmaceutically acceptable carrier.
14. The method of claim 8 , wherein the reduction in viability comprises increasing cytotoxicity in the cancer cells.
15. The method of claim 8 , wherein the reduction in viability comprises decreasing clonogenic survival of the cancer cells.
16. The method of claim 8 , wherein the reduction in viability comprises inducing apoptosis in the cancer cells.
17. The method of claim 8 , wherein the applying step is for an uninterrupted interval of time.
18. The method of claim 8 , wherein the applying step is interrupted by breaks.
19. A method of reducing the volume of a tumor disposed in a body of a living subject, the tumor including a plurality of cancer cells, the method comprising:
administering sorafenib to the subject; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 400 kHz,
wherein the sorafenib is administered to the cancer cells at a therapeutically effective concentration, the alternating electric field has a field strength of at least 1 V/cm in at least some of the cancer cells, and the applying step has a duration of at least 72 hours.
20. The method of claim 19 , wherein the frequency of the alternating electric field is between 120 and 180 kHz.
21. The method of claim 19 , wherein at least a portion of the applying step is performed simultaneously with at least a portion of the administering step.
22. The method of claim 19 , wherein the sorafenib has the general structure:
23. The method of claim 19 , wherein the cancer cells comprise hepatocellular carcinoma cells.
24. The method of claim 19 , wherein the sorafenib comprises a pharmaceutically acceptable carrier.
25. The method of claim 19 , wherein the applying step is for an uninterrupted interval of time.
26. The method of claim 19 , wherein the applying step is interrupted by breaks.